Posts Tagged ‘Unethical Clinical Trials’
Fraud during clinical trial exposed
Written by Sadaka Associates
Wednesday, 11 March 2009 21:20
Colorado Springs, CO (March 11, 2009) – On Friday, March 6, 2009, Coast IRB notified Criminal Fraud unit of the U.S. Department of Justice, the FBI, the FDA, and the Commonwealth of Virginia Department of Health Professions of a fraudulent clinical test. Coast Independent Review Board discovered that a protocol submitted for review of a medical device called Adhesiabloc by Device Med Systems of Clifton, Virginia, was fraudulent in violation of federal and state law. Upon receipt of proof of the fraud, Coast IRB and its CEO, Daniel Dueber, ordered immediate termination of the clinical trial, referred evidence to federal and state authorities for investigation and prosecution, and instituted measures to prevent a recurrence.
Coast IRB has urged authorities to investigate and prosecute the perpetrators whose actual identities remain unknown. Several felony fraud violations and potential RICO may have been committed. “We are informing the media in the hopes of alerting those who might otherwise become study subjects that this appears to be a fraudulent trial,” said Coast IRB CEO Daniel Dueber. “We are also doing so because we want other institutional review boards to learn of our experience and avoid review of this trial pending the result of federal and state investigations”.
Coast IRB discovered the evidence in a routine audit of the trial. Coast IRB discovered that credentials for the principal investigator were forged and that neither the principal investigator nor the medical director was licensed in Virginia. The Department of Health Professions from whence the forged license was allegedly issued reported no record of granting license to the person involved, no record of the license number listed on the forged credentials, and no issuance of licenses in the history of the Commonwealth in the format presented by the study sponsor. Coast IRB further discovered through on-site visit the address for the clinical trial organization where testing was presumably taking place, was in fact a strip mall. A 510(k) FDA number given for the medical device did not exist in FDA’s records.
Coast IRB is one of the largest independently owned IRB’s. Its mission is to protect the rights and welfare of subjects in clinical trials by providing ethical and thorough review. It is located in Colorado Springs, Colorado.
GSK accused of conducting unethical clinical trials in India
Written by Sadaka Associates
Thursday, 05 February 2009 09:32
The watchdog agency, Wemos International, which works to protect human subjects in clinical trials, today accused GlaxoSmithKline (GSK) and AstraZeneca of running unethical clinical trials in India.
GSK
GSK tested the breast cancer drug lapatinib in India. The drug, lapatinib, has been conditionally approved for the European market by the European Medicines Agency.’
There are currently around 400,000 Indian women with breast cancer, most of whom cannot afford to pay for the treatment they need. Den Boer says: ‘Participation in the lapatinib trial was practically inevitable since it was the only treatment option available to the women. They just had to accept the risks entailed in an experimental drug. GlaxoSmithKline has taken advantage of their vulnerable position. By now lapatinib is available in India, but most breast cancer patients cannot afford it.’
Tjalling van der Schors, hospital pharmacist and member of a Dutch medical ethics committee, is also critical of the trial, saying it would never have been passed by a Dutch ethics committee. ‘You only give cancer patients experimental treatments if normal protocols no longer work.’
AstraZeneca
AstraZeneca conducted two trials testing a new formulation of their drug Seroquel, which is used to treat schizophrenia. In both trials one group of participants was given the drug Seroquel and the other group was given a placebo.
Wemos International found two problems with this study. The first was design in these trials was not necessary. Placebo-controlled trials are not required to establish the efficacy of a new formulation of an approved drug. The second is that patients on placebo – in both trials – were harmed because they were deprived of an effective treatment until they suffered a relapse.
SOURCE: Wemos International
Contact Us | Vaginal Mesh Injury | Help for Gardasil Injury
Copying text from this site is prohibited by copyright law.
Please note that you are not considered a client until
you have signed a retainer agreement and your case has been accepted by us. Prior
results do not guarantee or predict a similar outcome with respect to any future matter.
ATTORNEY ADVERTISING
Law Offices of Sadaka Associates represents drug injury clients in drug injury lawsuits nationwide, including Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin and Wyoming.
We also serve the cities of New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose City, Detroit, Jacksonville, Indianapolis, San Francisco, Columbus, Austin, Memphis, Fort Worth, Baltimore, Charlotte, Boston, Seattle, Washington, Milwaukee, Denver, Louisville, Las Vegas, Nashville, Oklahoma City, Portland, Tucson, Albuquerque, Atlanta, Long Beach, Fresno, Sacramento, Mesa, Kansas City, Cleveland, Virginia Beach, Omaha, Miami, Oakland, Tulsa, Honolulu, Minneapolis, Colorado Springs, Arlington and Wichita.
__________________________________
Law Offices of Sadaka Associates LLC
20 North Van Brunt Street
Englewood, NJ 07631
Phone: 201-266-5670 Fax: 201-266-5671